3sbio, Inc. · HKEX:1530
3sbio — FY2020 Earnings Presentation
30 slides from 3sbio's earnings presentation, Mar 31, 2021
Slide 1: 2020 Annual Results Presentation
2020 Annual Results Presentation March 31 2021
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Content
Content • 2020 Highlights • R&D & Pipeline • Financial Performance • Q&A 3
Slide 4: 2020 Highlights
2020 Highlights Chairman, Director and CEO Dr. Jing LOU 4
Slide 5: Performance Summary
Performance Summary Revenue Adjusted Normalized Net Profit Attributable to increased YOY 5.1% to RMB5,587 million Owners of the Parent RMB million +17.5% +5.3% 1,416 1,345 47% 30% -46% 1,082 19% 926 743 TIPAIO rhEPO MANDI YISAIPU sales yoy EPO & SEPO sales yoy sales yoy increased 19% to sales yoy in
Slide 6: 2020 Highlights
2020 Highlights • 302H (HER2) NDA approval and product launched to the market • Sales Network：3,263 sales and marketing employees, 797 • 601A (VEGF) AMD and DME completed the patient enrollment distributors, and 2,263 third-party promoters in phase I trial, RVO and mpCNV initiated the preparation of
Slide 7: Core Products Maintained Significant Growth
Core Products Maintained Significant Growth Product Sample Revenue (RMB million) YoY % 2,323 TIPAO 19% 2,763 749 EPO & SEPO 30% 974 EPO® SEPO® 1,144 YISAIPU 615 (46%) 250 47% MANDI 368 1 852 Others 2% 863 2020 2019 1. Except for the above four core products, there are other products including but no
Slide 8: TPIAO
TPIAO Performance Outlook • Sound sales growth to RMB2,763 million yoy Multiple Driving Forces Boost Growth with the increased 19% to a new level Anticipation of RMB5 Billion Peak Sales • First-to-market and the only commercialized rhTPO Indications Expansion relevant product in the world which is r
Slide 9: rhEPO (EPO & SEPO)
rhEPO (EPO & SEPO) Performance Outlook • Sales rebounded yoy 30% to RMB974 million Brand Image & Production Capacity Reinforce the • Acceleration in the applications of EPIAO in IV and V Competence While Combination of Innovation and CKD patients and in CIA oncology indication in Mainland Imitation
Slide 10: YISAIPU
YISAIPU Performance Outlook Promote County Level Strategy, Accelerate Penetration • Dual impact of COVID-19 pandemic and fierce competition, to Expand Incremental Market sales slumped 46% to RMB615 million • New patients increased after Initiated 50% price cut while the • The number of domestic pati
Slide 11: CIPTERBIN
CIPTERBIN Performance Outlook • Approved by CDE and was included in NRDL in the same Seize the opportunity of NRDL, Position in the Core year Track，and Estimated Peak Sales reach RMB1.5 billion • Self-developed, China first innovated under the new label Inetetamab was included in Clinical Guidance1
Slide 12: MANDI
MANDI Performance Outlook • Sales surged yoy 47% to RMB368 million • Market share took up 75%，occupied the absolute Take a Lead in the Hair Loss Frontier Segment and dominate position Aesthetic Medicine Enhances Peak Sale Expectation • Online sales yoy soared ~100%，Ranked Top 1 in the same category
Slide 13: Multiple Catalysts Expedite Sustainable Growth in the Recent 2-3 Years
Multiple Catalysts Expedite Sustainable Growth in the Recent 2-3 Years 01 TPIAO National Negotiation for 2021 NRDL had been done. A unique and exclusive product with a rigid clinical demand, and TPIAO new effective price continues to accelerate the penetration rate to support solid growth >10% in cl
Slide 14: R&D and Pipeline
R&D and Pipeline Sunshine Guojian President Dr. Zhenping ZHU 14
Slide 15: R&D Progress
R&D Progress • 608 (IL-17A) completed patient enrollment in • 302H (HER2) NDA approval and product Phase I launched to the market • 610 (IL-5) IND approved and completed patient enrollment in Phase Ia clinical trial • 304R (CD20) in the progress of Phase III trial site inspection • 611 (IL-4) IND ap
Slide 16: Robust and Innovative Product Pipeline
Robust and Innovative Product Pipeline Pre-clinical IND Phase I Phase II Phase III & BE NDA 6 4 7 5 10 + 2 Clinical Trial New Drug Therapeutic Product Candidate Pre-clinical Phase I Phase II Phase III Product Approval Application Registration SSS06 Long-acting EPO RD001 Long-acting EPO SSS17 HIF inh
Slide 17: Biologics Pipeline in Oncology
Biologics Pipeline in Oncology >10 Candidates in the Clinical Trial Pre-clinical：3+ NDA & Clinical Trial: 7 4 临床中：4个品种 1 1 1 IND Phase I Phase II Phase III Pre- Product Target Indication clinical IND Phase I Phase II Phase III HER-2 Layout 304R CD20 NHL 602 EGFR Colorectal Cancer NSCLC, Gastric HER2
Slide 18: Biologics Pipeline in Nephrology, Auto-immune, and Others
Biologics Pipeline in Nephrology, Auto-immune, and Others Pre- Therapeutic Product Target Indication Clinical IND Phase I Phase II Phase III NDA FOCUS ON GLOBAL BLOCKBUSTER 301S TNFa RA, PS, AS - New amino acid sequence targeting IL- RA, AS, Ulcerative SSS07 TNFa 17A colitis 608 Auto- - Global sales
Slide 19: Small Molecule Combo
Small Molecule Combo Nephrology Auto-immune Oncology Dermatology Sevelamer Carbonate (SSS13) Apremilast (AP506) Trifluridine and Tipiracil Minoxidil Foam (MN709) • Oral treatment of Hyperphosphatemia • Oral treatment of PS and • NDA filed in 2020 Psoriatic Arthritis Hydrochloride Tablets • Foam Type
Slide 20: Integrated International Strategic Collaborations
Integrated International Strategic Collaborations Oncology Nephrology • China rights of Bevacizumab biosimilar named SB8 • American right of Pegsiticase specialized in hyperuricemia, and • Two selected Verseau’s PLGS-1 and VSIG-4 refractory gout targeted antibodies in immuno-oncology collaborations
Slide 21: R&D Outlook
R&D Outlook Estimation in 2025 601A 611 612 613 705,706,707 617 VSIG-4 SSS17 （RVO/pmCNV) Phase Estimated III 10+ Peak Sales 161 30 10 30 30 10-20 - 15 2 （RMB bn） Other 601A 609A possible 602 610 SB16 RD001 SSS06 File （DME） （China） candidates NDA 7+ 16 1 5 15 3 15 - 20 2 20 2 >10 small 609A 601A New
Slide 22: Integrated R&D Centers and Platforms
Integrated R&D Centers and Platforms Shenyang Shanghai Shenzhen Hangzhou Biologics/Chemicals Biologics Biologics Chemicals GMP Molecular construction The world-class Development Key technical links ie. Medium technology platform structural Large-scale high- experience of high- animal immunity, cell
Slide 23: Comprehensive Manufacturing Capabilities Adhere to Int'l Quality Standards
Comprehensive Manufacturing Capabilities Adhere to Int’l Quality Standards ⚫ All 10 production lines for different dosage forms are ⚫ Plant certified by 11 countries, including certified by GMP in 2010 Ukraine, Brazil and Mexico ⚫ QA personnel represent 20%+ of all manufacturing ⚫ QA personnel repre
Slide 24: Financial Performance
Financial Performance Chief Financial Officer Mr. Fei WANG 24
Slide 25: Main Revenue Continuously Maintains Steady Growth while Gross Profit retains 80%+
Main Revenue Continuously Maintains Steady Growth while Gross Profit retains 80%+ RMB million Total Revenue Gross Profit +18.9% +5.1% +17.2% +3.0% 5,318 5,588 4,525 4,393 4,584 3,707 3,734 3,058 2,797 2,395 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Net Profit Attributable to Owners of the Pa
Slide 26: Continuously Invest into R&D while Sales and Management Fees are Gradually Reduced
Continuously Invest into R&D while Sales and Management Fees are Gradually Reduced Share Scheme Cost of Sales RMB30 million Management Fee CAGR 18.9% Normalized 4% 15% 20.2 Management Fee 27% 19.5 20 16.9 31% 13.3 CAGR 10.2% 10 10.2 113% -34% 5% 1% 3.5 0 2016 2017 2018 2019 2020 1.0 Sales Expense 36
Slide 27: Significant growth of both net assets and total assets in 2020
Significant growth of both net assets and total assets in 2020 while the debt to asset ratio continuously decreases Total asset RMB billion Debt to asset ratio (%) +19.4% +12.5% 177 45 45 148 138 110 40 39 39 36 35 30 30 28 26 25 2016 2017 2018 2019 2020 Include CB 19 20 14 15 12 Net asset RMB billi
Slide 28: Excellent Cash Flow and Abundant Cash Reserves
Excellent Cash Flow and Abundant Cash Reserves Operation cash flow (RMB billion) Cash and cash equivalents (RMB billion) （including financial products） 2016 10 +74.2% +43.8% 45 2017 11 31 2018 12 26 19 2019 19 10 2020 13 2016 2017 2018 2019 2020 28
Slide 29: Q&A Management Team
29 Q&A Vv Management Team
Slide 30: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE